Although previous studies in patients with NSCLC have revealed specific immune cell populations related to tumor immunity after PD-1 blockade, none have addressed the usefulness of a clinical test that could address both the phenotypic and functional characteristics of circulating immune cells (8, 9). The gene discussed is PDCD1; the disease is neoplasm.